Brian V Fix1, Richard J O'Connor1, Neal Benowitz2, Bryan W Heckman3, K Michael Cummings3, Geoffrey T Fong4, James F Thrasher5. 1. Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY. 2. UCSF School of Medicine, San Francisco, CA. 3. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC. 4. Department of Psychology, University of Waterloo, Waterloo, ON, Canada. 5. Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia SC; Department of Tobacco Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
Abstract
INTRODUCTION: The ratio of trans 3'-hydroxycotinine (3HC) to cotinine (nicotine metabolite ratio [NMR]) is a biomarker of the rate of nicotine metabolism, with higher NMR indicating faster metabolism. Higher NMR has been found to be associated with higher daily cigarette consumption and less success stopping smoking in cessation trials. This study examines differences in NMR among population-based samples of smokers in the five countries and explores the relationship between NMR and smoking abstinence. METHODS: Participants (N = 874) provided saliva samples during International Tobacco Control (ITC) surveys in the United States, United Kingdom, Mauritius, Mexico, and Thailand conducted in 2010/2011 with follow-up surveys in 2012/2013. When all samples were received, they were sent to a common laboratory for analysis using liquid chromatography and tandem mass spectroscopy. RESULTS: There was significant variation in NMR across countries (F = 15.49, p < .001). Those who reported smoking at follow-up had a mean NMR of 0.32, compared to a mean NMR of 0.42 in participants who reported that they had stopped (F = 8.93; p = .003). Higher mean NMR values were also associated with longer quit duration (p = .007). There was no substantial difference in NMR between current smokers who made a failed quit attempt and those who made no attempt-both had significantly lower NMR compared to those who quit and remained abstinent. Smokers with a higher NMR were more likely to report that they stopped smoking compared to those with a lower NMR (odds ratio = 2.67; 95% confidence interval: 1.25 to 5.68). CONCLUSIONS: These results suggest faster nicotine metabolizers may be less likely to relapse following a quit attempt. This finding differs from results of clinical trials testing stop smoking medications, where slower metabolizers have been found to be more likely to maintain abstinence from smoking. IMPLICATIONS: Results of this study suggest faster nicotine metabolizers may be less likely to relapse following a quit attempt. This finding differs from results of clinical trials testing stop smoking medications, where slower metabolizers have been found to be more likely to maintain abstinence from smoking.
INTRODUCTION: The ratio of trans 3'-hydroxycotinine (3HC) to cotinine (nicotine metabolite ratio [NMR]) is a biomarker of the rate of nicotine metabolism, with higher NMR indicating faster metabolism. Higher NMR has been found to be associated with higher daily cigarette consumption and less success stopping smoking in cessation trials. This study examines differences in NMR among population-based samples of smokers in the five countries and explores the relationship between NMR and smoking abstinence. METHODS: Participants (N = 874) provided saliva samples during International Tobacco Control (ITC) surveys in the United States, United Kingdom, Mauritius, Mexico, and Thailand conducted in 2010/2011 with follow-up surveys in 2012/2013. When all samples were received, they were sent to a common laboratory for analysis using liquid chromatography and tandem mass spectroscopy. RESULTS: There was significant variation in NMR across countries (F = 15.49, p < .001). Those who reported smoking at follow-up had a mean NMR of 0.32, compared to a mean NMR of 0.42 in participants who reported that they had stopped (F = 8.93; p = .003). Higher mean NMR values were also associated with longer quit duration (p = .007). There was no substantial difference in NMR between current smokers who made a failed quit attempt and those who made no attempt-both had significantly lower NMR compared to those who quit and remained abstinent. Smokers with a higher NMR were more likely to report that they stopped smoking compared to those with a lower NMR (odds ratio = 2.67; 95% confidence interval: 1.25 to 5.68). CONCLUSIONS: These results suggest faster nicotine metabolizers may be less likely to relapse following a quit attempt. This finding differs from results of clinical trials testing stop smoking medications, where slower metabolizers have been found to be more likely to maintain abstinence from smoking. IMPLICATIONS: Results of this study suggest faster nicotine metabolizers may be less likely to relapse following a quit attempt. This finding differs from results of clinical trials testing stop smoking medications, where slower metabolizers have been found to be more likely to maintain abstinence from smoking.
Authors: Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman Journal: J Nucl Med Date: 2015-08-13 Impact factor: 10.057
Authors: Robert A Schnoll; Tony P George; Larry Hawk; Paul Cinciripini; Paul Wileyto; Rachel F Tyndale Journal: Psychopharmacology (Berl) Date: 2014-01-09 Impact factor: 4.530
Authors: Jon O Ebbert; Herbert H Severson; Brian G Danaher; Neal L Benowitz; Darrell R Schroeder Journal: Nicotine Tob Res Date: 2015-05-14 Impact factor: 4.244
Authors: Caryn Lerman; Robert A Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; E Paul Wileyto; Gary E Swan; Neal L Benowitz; Daniel F Heitjan; Rachel F Tyndale Journal: Lancet Respir Med Date: 2015-01-12 Impact factor: 30.700
Authors: Li-Shiun Chen; Sarah M Hartz; Timothy B Baker; Yinjiao Ma; Nancy L Saccone; Laura J Bierut Journal: Pharmacogenomics Date: 2018-11-16 Impact factor: 2.533
Authors: Gideon St Helen; Neal L Benowitz; Jasjit S Ahluwalia; Rachel F Tyndale; Newton Addo; Steven E Gregorich; Eliseo J Pérez-Stable; Lisa Sanderson Cox Journal: J Natl Med Assoc Date: 2019-05-11 Impact factor: 1.798
Authors: Terril L Verplaetse; MacKenzie R Peltier; Walter Roberts; Kelly E Moore; Brian P Pittman; Sherry A McKee Journal: Nicotine Tob Res Date: 2020-07-16 Impact factor: 4.244
Authors: Walter Roberts; Phillip L Marotta; Terril L Verplaetse; MacKenzie R Peltier; Catherine Burke; Vijay A Ramchandani; Sherry A McKee Journal: Drug Alcohol Depend Date: 2020-08-05 Impact factor: 4.492
Authors: Harvey J Murff; Robert A Greevy; Reesha S Sanghani; Katherine E Hartmann; Tina V Hartert; Cornelia R Graves; Scott S Lee; Hilary A Tindle Journal: Trials Date: 2021-12-14 Impact factor: 2.279
Authors: Patricia Di Ciano; Rachel F Tyndale; Esmaeil Mansouri; Christian S Hendershot; Alan A Wilson; Dina Lagzdins; Sylvain Houle; Isabelle Boileau; Bernard Le Foll Journal: Int J Neuropsychopharmacol Date: 2018-06-01 Impact factor: 5.176